Latest Heparin Stories
By Elizabeth Weise Frustrated after twice asking a Cincinnati-based manufacturer of medical products to recall contaminated heparin, the Food and Drug Administration took the rare step Thursday of sending U.S. marshals to seize 11 lots of the blood-thinning drug.
The U.S. Food and Drug Administration announced the Thursday seizure of 11 lots of contaminated heparin from Celsus Laboratories Inc. in Cincinnati.
Regado Biosciences has completed enrollment in the Phase IIa clinical study of its REG1 anticoagulation system in patients undergoing elective percutaneous coronary intervention.
DURHAM, N.C., Oct. 10 /PRNewswire/ -- Regado Biosciences, Inc., announced today the Company has completed enrollment in the Phase IIa clinical study of its REG1 Anticoagulation System in patients undergoing elective percutaneous coronary intervention (PCI).
FOR U.S. AUDIENCES ONLY The Medicines Company (NASDAQ:MDCO) -- today announced that 1-year clinical data from the HORIZONS-AMI trial, comparing Angiomax(R) (bivalirudin) vs.
Leg compression combined with medication such as heparin is more effective at preventing blood clots than either alone, U.S. researchers said.
PolyMedix, a biotechnology company, has initiated dosing and commenced a Phase I clinical study in the US with its anticoagulant reversing agent PMX-60056 under an investigational new drug application filed with the FDA. This first Phase I clinical trial will assess the safety of PMX-60056.
The Joint Commission on Wednesday ordered new tougher restrictions on the use of blood thinners including heparin.
PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in the U.S.
The government yesterday began posting a list of prescription drugs under investigation for potential safety problems, in an effort to better inform doctors and patients. The first list is a bare-bones compilation naming 20 medications and the potential issue for each.